APAC Innovation: Delivery Formats, Ageing Interventions, and Novel Ingredient Applications Drive Growth
Manufacturers in the Asia-Pacific region are capitalising on sophisticated delivery formats, targeted anti-ageing interventions, and niche ingredient applications for specific demographics, reflecting advanced R&D and evolving consumer demands.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Singapore, Singapore — 21 March 2025
The Asia-Pacific nutraceutical market is experiencing significant evolution, driven by advancements in ingredient technology and consumer demand for highly specialised and engaging products. Delivery format innovation is at the forefront, with Lonza Capsules & Health Ingredients (CHI) observing a surge in solutions that blend scientific efficacy with enhanced sensory experiences and personalised health support. This trend, articulated by Shelby Linville, Associate Director of Global Product Marketing at Lonza CHI, indicates a clear pathway for manufacturers to differentiate offerings beyond traditional capsules and tablets.
Ingredient suppliers are simultaneously advancing research into highly targeted health benefits. Vixxol, a Korean distributor, is initiating a clinical trial on white mulberry leaf extract (Reducose) to assess its impact on post-meal blood glucose regulation and GLP-1 production. This move underscores a growing emphasis on ingredients with clinically validated metabolic benefits, directly addressing prevalent health concerns in the region. Similarly, dsm-firmenich is strategically focusing on four of the 12 hallmarks of ageing: cellular senescence, mitochondrial dysfunction, chronic inflammation, and dysbiosis. Gabriele Civiletto, associate principal scientist at dsm-firmenich, highlighted this multi-faceted approach at the Founders Longevity Forum in Singapore, signalling a move towards comprehensive, science-backed anti-ageing formulations.
Beyond traditional adult demographics, suppliers are exploring niche 'blue ocean' markets. Indian botanical supplier Bio-gen Extracts is conducting a six-month clinical trial in Australia to investigate the visuocognitive benefits of its patented lutein and zeaxanthin ingredient, Lute-Gen, in teenagers. This study aims to validate a novel application for established ingredients, targeting an underserved demographic in cognitive and eye health. Concurrently, FrieslandCampina reports increasing traction for MFGM (milk fat globule membrane) in infant and children’s nutrition across APAC. Citing increased consumer awareness of early-life immunity, the company notes MFGM's inclusion in products like Mead Johnson’s Enfamil Enspire 1 infant formula, supported by its latest in vitro study demonstrating antiviral activity.
What this means for Singapore
Singaporean manufacturers must prioritise investment in advanced delivery technologies to meet rising consumer expectations for sensory appeal and personalisation, potentially securing a 15-20% price premium. Regulatory compliance for novel formats and claims, particularly for targeted anti-ageing and cognitive health, will be critical under HSA guidelines. Brand owners should leverage clinically-backed ingredients like white mulberry extract for metabolic health and MFGM for paediatric immunity to gain a competitive edge. Opportunities exist in co-development partnerships with ingredient suppliers focusing on specific 'hallmarks of ageing' to create differentiated, high-margin products for Singapore's increasingly health-conscious and ageing population.
What to watch next
- Monitor the outcome of Vixxol's white mulberry leaf extract clinical trial, expected to conclude Q4 2025, for potential new blood glucose management claims.
- Observe the completion and publication of Bio-gen Extracts' Australian clinical trial on Lute-Gen in teenagers, anticipated by late 2025, to assess new market entry points for cognitive health.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.